Economic evaluation of hemodialysis. Analysis of cost components based on patient-specific data;Evaluación económica de la hemodiálisis. Análisis de los componentes del coste basado en datos individuales

Nefrologia

Volumn 30, Issue 4, 2010, Pages 403-412

  Lorenzo, V ^a   Perestelo, I ^b   Barroso, M ^c   Torres, A ^a   Nazco, J ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b Consejería de Sanidad del Gobierno Autónomo de Canarias ^*  (Spain)

^c Servicio Canario de la Salud   (Spain)

Author keywords

Costs of illness; Diagnosis related groups; End stage renal disease; Hemodialysis

Indexed keywords

ARTICLE; CLINICAL TRIAL; COST; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; STATISTICS;

COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 77955991776     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Jun.10264     Document Type: Article

References (35)

1. US Renal data system: USRDS 2005 Annual Data Report, Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007
2. ERA-EDTA Registry: ERA-EDTA Registry 2002 Annual Report Academic Medical Center, Amsterdam, The Netherlands, May 2004. Disponible en: http://www.era-edta-reg.org/annrep.jsp
3. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.[Pubmed]
4. Schena FP. Epidemiology of end-stage renal disease: Internationa comparisons of renal replacement therapy. Kidney Int 2000(Supp 57):S39-S45
5. Van Dijk PC, Jager KJ, Stengel B, et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005;67:1489-99.[Pubmed]
6. Spanish Registry of Renal Patients. Dialysis and transplantation. Preliminary report 2007. Disponible en http://www.senefro.org/modules.php?name=subsection&idsection=7&idsubsection=128
7. Ceballos M, Lopez-Revuelta K, Saracho R, et al. Dialysis and transplant patients Registry of the Spanish Society of Nephrology Nefrologia 2005;25:121-9.[Pubmed]
8. Lorenzo V, Martín Urcuyo B. Análisis epidemiológico del incremento de insuficiencia renal terminal asociada a diabetes mellitus tipo 2 Nefrologia 2000;20:77-81.[Pubmed]
9. Lorenzo V, Sánchez E, Vega N, Hernández D. Renal replacement therapy in the Canary Islands: demographic and survival analysis J Nephrol 2006;19:97-103.[Pubmed]
10. Lorenzo V Saracho R, Zamora J, et al. Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria. Nephrol Dial Transplant 2010;25:835-41.[Pubmed]
11. Hernández-Jaras J, García H, Bernat A, Cerrillo V Aproximación a análisis de costes de diferentes tipos de hemodiálisis mediante unidades relativas de valor. Nefrologia 2000;20:284-90.[Pubmed]
12. Lamas J, Alonso M, Saavedra J, et al. Costes de la diálisis crónica en un hospital público: mitos y realidades. Nefrologia 2001;21:283-94.[Pubmed]
13. De Vecchi AF, Dratwa M, Wiedemann ME. Healthcare systems and end-stage renal disease (ESRD) therapies -an international review costs and reimbursement/funding of ESRD therapies. Nephrol Dia Transplant 1999;14(Suppl 6):31-41.[Pubmed]
14. Lee H, Manns B, Taub K, et al. Cost-analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2001;40:611-22
15. Ploth DW, Shepp PH, Counts C, Hutchison F. Prospective analysis of global costs for maintenance of patients with ESRD. Am J Kidney Dis 2003;42:12-21.[Pubmed]
16. Klarenbach SW. Economic evaluation in renal disease. J Nephro 2007;20:251-9.[Pubmed]
17. Khan IH, Catto GR, Edward N, et al. Influence of coexisting disease on survival on renal-replacement therapy. Lancet 1993;341:415-8.[Pubmed]
18. Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM (ed). Evaluation of Chemotherapeutic Agents. C9olumbia:Columbia Univ. Press, 1949.
19. Beddhu S, Bruns FJ, Saul M, et al. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 2000;108:609-13.[Pubmed]
20. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982;60:429-62.[Pubmed]
21. Boletín Oficial de Canarias N.° 257, pág. 26152, 24 de diciembre de 2008
22. Registro de Altas de los Hospitales Generales del Sistema Naciona de Salud. Ministerio de Sanidad y Política Social. Disponible en http://www.msc.es/estadEstudios/estadisticas/cmbd.htm
23. Base de datos de costes sanitarios SOIKOS. Barcelona: SOIKOS, 2005
24. Thompson SG, Barber JA, How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-200.[Pubmed]
25. Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Tria (IDNT) in the Belgian and French settings. Nephrol Dia Transplant 2003;18:2059-66.[Pubmed]
26. Gerth WC, Remuzzi G, Viberti G, et al. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Kidney Int 2002;(Suppl):S68-S72.[Pubmed]
27. Lamping DL, Constantinovici N, Roderick P, et al. Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study. Lancet 2000;356:1543-50.[Pubmed]
28. Costa-Scharplatz M, Van Asselt AD, Bachmann LM, et al. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor. Pharmacogenet Genomics 2007;17:359-68.[Pubmed]
29. Icks A, Haastert B, Gandjour A, et al. Costs of dialysis -a regiona population-based analysis. Nephrol Dial Transplant 2009
30. Pons R, Torregrosa E, Hernández-Jaras J, et al. El coste de tratamiento farmacológico en la enfermedad renal crónica Nefrologia 2006;26:358-64.[Pubmed]
31. Lorenzo V, Martín-Malo A, Pérez-García R, et al. Prevalence, clinica correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephro Dial Transplant 2006;21:459-65.[Pubmed]
32. Sehgal AR, Dor A, Tsai AC. Morbidity and cost implications of inadequate hemodialysis. Am J Kidney Dis 2001;37:1223-31.[Pubmed]
33. Jotkowitz AB, Rabinowitz G, Raskin SA, et al. Do patients with diabetes and low socioeconomic status receive less care and have worse outcomes? A national study. Am J Med 2006;119:665-9.[Pubmed]
34. Hirth RA, Held PJ, Orzol SM, Dor A. Practice patterns, case mix, Medicare payment policy, and dialysis facility costs. Health Serv Res 1999;33:1567-92.[Pubmed]
35. López-Bastida J, Oliva-Moreno J, Perestelo-Pérez L, Serrano-Aguilar P. The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain. BMC Health Serv Res 2009;9:55-9.[Pubmed]